Excelsior Biopharma Inc

Excelsior Biopharma Inc has a market price of 23.55 TWD per share and a market capitalization of 1,096,911,900 TWD, with a price-to-book ratio of 1.03 and a price-to-tangible-book ratio of 1.03. The company's liquidity position is strong, with 497,726,000 TWD in cash and equivalents and a current ratio of 4.14, indicating a robust ability to meet short-term obligations. However, the company's operating cash flow is negative at -1,425,000 TWD, and its free cash flow is -203,788,000 TWD, suggesting ongoing cash outflows from operations.

The company's profitability is weak, with a net loss of 33,678,000 TWD and an operating loss of 28,944,000 TWD. Its return on equity is -3.17%, and its return on assets is -2.00%, both significantly below the industry norms for pharmaceutical companies. The gross profit margin is 44.19%, which is in line with the industry average, but the operating margin is -15.22%, indicating poor operational efficiency.

Excelsior Biopharma Inc's revenue is concentrated in a single business segment, with no disclosed geographic diversification. The company's revenue of 190,111,000 TWD is entirely attributed to its pharmaceutical operations, and there is no information on regional revenue distribution. This lack of diversification may expose the company to higher business risks if demand for its products declines in its primary market.

The company's growth trajectory is uncertain, with no disclosed revenue growth in the most recent period. The operating loss and negative cash flows suggest that the company is not currently generating sufficient revenue to cover its costs and invest in future growth. The capital expenditure of -187,183,000 TWD indicates significant investment in infrastructure or R&D, but the negative value suggests a reduction in capital spending.

The risk assessment for Excelsior Biopharma Inc indicates low liquidity and dilution risks, with no immediate filing-based flags detected. The company's debt-to-equity ratio is 0.42, which is relatively low, and its total liabilities of 622,607,000 TWD are well below its total equity of 1,063,256,000 TWD. However, the company's negative net income and operating cash flow may limit its ability to service debt or fund operations without external financing.

Recent events for Excelsior Biopharma Inc include the last actual EPS of 0.73 TWD, as reported by analysts. There are no disclosed recent filings or transcripts that provide additional insight into the company's operations or strategic direction.

Free cash flow improved by 91.9% year-over-year, indicating a significant reduction in cash burn relative to the prior period.

Operating income surged 83.5% year-over-year, demonstrating substantial improvement in core operational efficiency despite ongoing losses.

Net income improved by 81.6% year-over-year, showing a marked decrease in the magnitude of reported net losses.

The company maintains a low dilution risk profile, suggesting limited immediate threat to existing shareholder equity value.

Liquidity risk is assessed as low, implying the company currently possesses sufficient resources to meet short-term obligations.

The company faces high credit risk, indicating potential difficulties in meeting debt obligations or securing favorable financing terms.

Long-term debt increased to TWD 511.3 million in the latest period, raising concerns about growing leverage and financial flexibility.

Revenue TWD 218.2M; Operating income -TWD 17.7M.

• ▍Revenue TWD 218.2M
• ▍Operating income -TWD 17.7M
• ▍Net margin -10.2%

Revenue TWD 212.9M; Operating income -TWD 18.3M.

• ▍Revenue TWD 212.9M
• ▍Operating income -TWD 18.3M
• ▍Net margin -9.8%

Revenue TWD 190.1M; Operating income -TWD 28.9M.

• ▍Revenue TWD 190.1M
• ▍Operating income -TWD 28.9M
• ▍Net margin -17.7%

Revenue TWD 771.6M, +14,9% YoY; Operating income −187,5% YoY.

• ▍Revenue TWD 771.6M, +14,9% YoY
• ▍Operating income −187,5% YoY
• ▍Net income −169,6% YoY
• ▍Free cash flow −330,6% YoY
• ▍Net margin -11.8%